Abstract. Cell signaling pathways and protein translation are crucial for understanding malignant transformation. 4E-BP1 and the eIF4F complex regulate cap-dependent translation. We investigated how 4E-BP1 and eIF4E phosphorylation status affects in vitro and in vivo cell proliferation in a breast cancer model. Cells from 2 breast carcinoma lines (MDA-MB 231 and MDA-MB 468) and human fibroblasts (IMR90 cells) were infected in vitro with a retrovirus carrying a wild-type 4E-BP1 or a mutant 4E-BP1 unable to hyperphosphorylate. Overexpression of the mutant 4E-BP1 induced a significant decrease in cell proliferation in IMR90 and MDA-MB 468 cells, but not in MDA-MB 231 cells. A correlation was observed between baseline-phosphorylated eIF4E (p-eIF4E) levels and sensitivity to 4E-BP1 transduction. By co-immunoprecipitation, p-eIF4E seemed to present lower affinity for 4E-BP1 than total eIF4E in MDA-MB 468 cells. After treatment with CGP57380, the MAP kinase-interacting kinase (MNK) inhibitor, downregulation of p-eIF4E levels was associated with an increase of E-cadherin and β-catenin protein expression. These results provide evidence that 4E-BP1 transduction leads to a decrease in cell proliferation, and that high p-eIF4E levels may counteract the suppressor effect of 4E-BP1. We propose that high p-4E-BP1 and p-eIF4E levels are central factors in cell signaling and reflect the oncogenic potential of cell signaling pathways in breast cancer.
Introduction
Eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) plays a critical role in controlling biological processes, such as protein synthesis, cell survival and growth. Hence, it is not surprising that alterations in 4E-BP1 regulation are associated with tumor development and progression (1) . We have previously proposed that the phosphorylated form of this protein (p-4E-BP1) acts as a funnel factor or bottleneck through which the transforming signals converge, channeling the oncogenic proliferative signal (1) . Work in our laboratory with a large series of breast, ovarian, prostate and endometrial tumors has shown a correlation between p-4E-BP1 and the clinical and pathologic characteristics of tumors, regardless of the upstream oncogenic alterations (2-4).
Other authors have reported similar results in breast carcinomas, melanomas and prostate cancer (5) (6) (7) (8) . In a study on breast cancer, phosphorylation of AKT, mTOR and 4E-BP1 was associated with tumor development and progression (7) . Transfer of 4E-BP1 phosphorylation site mutants into breast carcinoma cells suppresses their tumorigenicity (9) . Kremer et al (8) investigated the expression patterns of several biomarkers of the mTOR pathway in prostate cancer and observed that 4E-BP1 levels, in combination with mTOR and PTEN activation, were among the best biomarkers of prostate intraepithelial neoplasia (PIN). Other reports have associated p-4E-BP1 with patient survival in prostate cancer (5) and melanoma (6) .
The importance of 4E-BP1 lies in its control of cap-dependent translation initiation complex assembly. Binding of 4E-BP1 to eIF4E prevents formation of the cap-dependent mRNA translation initiation complex, eIF4F (composed of three subunits, eIF4E, eIF4A and eIF4G), and consequent ribosome binding. 4E-BP1 phosphorylation results in eIF4E release, thereby enabling cap-translation initiation. 4E-BP1 is phosphorylated at six serine/threonine sites, and the two ultimate phosphorylations, at Thr70 and Ser65, are considered responsible for eIF4E dissociation. In a specific group of mRNAs, all of them with a lengthy and highly structured 5' UTR, translation is dependent on eIF4E availability. The proteins encoded by these mRNAs, such as c-myc, cyclin D1, VEGF and ODC, are related to cell growth and the cell cycle.
The inhibitory binding protein 4E-BP1 regulates eIF4E availability. Accordingly, eIF4E levels are substantially elevated in several types of cancers (10) . eIF4E drives malignancy when it is overexpressed in experimental models (11) , whereas reducing eIF4E expression effectively inhibits the growth of breast and prostate cancer xenografts, and head and neck squamous carcinoma cells (12, 13) . Moreover, eIF4E activation is significantly related to reduced patient survival in human prostate cancer, and lung cancer (5) . eIF4E can be regulated postranscriptionally by two different mechanisms: binding to translational repressor 4E-BPs and phosphorylation by MNKs (14) (15) (16) . Although eIF4E phosphorylation on Ser209 was discovered some time ago, it remains unclear whether phosphorylation increases or decreases eIF4E affinity for the cap-structure. Early data indicated that eIF4E phosphorylation increased the affinity for capped mRNAs, whereas other studies have shown that eIF4E phosphorylation actually decreases affinity for the cap-structure and capped oligoribonucleotides (15, (17) (18) (19) (20) .
The aim of this study was to analyze how 4E-BP1 phosphorylation combined with eIF4E phosphorylation affects cell proliferation in vitro and in vivo in a breast cancer model. We show that cells expressing high phosphorylated eIF4E (p-eIF4E) levels can be resistant to blocking of cap-dependent translation with a mutant 4E-BP1 and that downregulation of p-eIF4E associates with an increase of E-cadherin and β-catenin protein levels.
Materials and methods
Plasmid constructs. pBABE-4E-BP1wt and pBABE-4E-BP1 (4 Ala) constructs were kindly provided by Dr N. Sonenberg (McGill University, Montreal, Canada). pBABE-4E-BP1 (4 Ala) contains a mutated form of 4E-BP1. The mutations are on the four most relevant 4E-BP1 phosphorylation sites: Thr 37/46, Thr 70 and Ser 65. Both wild-type (wt) and mutant (mut) 4E-BP1 contain two amino terminal hemagglutinin (HA) tags.
Cell lines and cell culture. The following cell lines were used in the study: IMR90 human primary fibroblasts (ATCC, American Type Culture Collection, Middlesex, UK), and two breast carcinoma cell lines, MDA-MB 231 and MDA-MB 468 (ATCC). Cells were maintained in standard DMEM (Dulbecco's modified Eagle's medium) growth medium supplemented with 10% fetal calf serum and antibiotics. MDA-MB 468 cells were treated with 40 µM of MNK inhibitor overnight (CGP 57380, Tocris Bioscience, Ellisville, MO).
Cell transfection and retroviral transduction. To generate cell lines that stably express 4E-BP1 and mutant 4E-BP1, pBABE constructs were transiently transfected into a packaging cell line (GP-293, Clontech, Heidelberg, Germany) according to the manufacturer's instructions. For retroviral infection, cell monolayers were incubated in the presence of the retroviruscontaining supernatant and 4 µg/ml polybrene (Sigma-Aldrich Taufkirchen, Germany) for 24 h. Infection was repeated the next day. Twenty-four hours after the second infection, medium supplemented with puromycin (0.7 µg/ml, Sigma-Aldrich) was added, and cells underwent selection for 3 days to eliminate uninfected cells. Amersham Pharma-Biotech) was added, and the solution was gently mixed for 1 h at 4˚C. Samples were centrifuged at 12,000 x g for 20 sec. The pellet was washed 3 times with 1 ml lysis buffer, and suspended in 30 µl sample reducing buffer (1% SDS, 100 mM DTT, 50 mM Tris, pH 7.5). The suspension was heated to 95˚C for 3 min and centrifuged at 12,000 x g for 20 sec to remove the beads. Lastly, 1 µl of 0.1% bromophenol blue was added, and the supernatant was analyzed by Western blot analysis as described above. These immunoprecipitation experiments were performed three times each, with similar results.
Tumor formation assay. Four-week-old athymic female BALB/C nude mice were purchased from Harlan Laboratories (San Pietro al Natisone, Italy) and housed for 1 week before the experiment. A 5x10 6 amount of MDA-MB 468 or MDA-MB 231 cells was suspended in 100 µl of PBS and injected subcutaneously in the flanks of 3 animals (right and left). Tumor growth was monitored by daily measurement. The latency period to tumor formation was defined as the interval from cell inoculation to the time when tumors became visible in at least 50% of animals. Mice were sacrificed 54 days after injection. The tumor was extracted and weighted.
Statistical analysis. Statistical analyses with the Statistical
Package for the Social Sciences (SPSS, version 13.0; SPSS Inc., Chicago, IL) were performed to analyze tumorigenicity. The tumor weights (MDA-MB 468/vector versus MDA-MB 468/4E-BP1 wt and MDA-MB 468/4E-BP1mut, and the same for MDA-MB 231) were compared using the Kruskal-Wallis test. Statistical significance was set at a two-tailed p≤0.05.
Results
Study of the eIF4F complex formation. It is known that the phosphorylation status of 4E-BP1 determines binding to eIF4E. Electrophoresis of 4E-BP1 polyacrylamide gel separates three different isoforms: α, β and γ. The γ band represents the most highly phosphorylated band (Ser 65, Thr 70 and Thr 37/46), the β band represents phosphorylations at Thr 70 and Thr 37/46, and the α band corresponds to the least phosphorylated form, Thr 37/46 (9, 21, 22) . To assess whether 4E-BP1, eIF4E and eIF4G might be involved in eIF4F complex formation and how their phosphorylation status could affect cell proliferation, we studied two breast carcinoma cell lines (MDA-MB 231 and MDA-MB 468) and human primary fibroblasts (IMR90). Previously, baseline 4E-BP1, eIF4E and eIF4G levels were determined in the three cell lines studied (Fig. 1A) . The results showed that p-eIF4E expression levels were lower in MDA-MB 468 than in MDA-MB 231. Conversely, the 4E-BP1 γ and β band levels were higher in MDA-MB 468. This upward mobility shift reflects hyperphosphorylation of 4E-BP1, which reduces its ability to bind eIF4E and enhances protein translation (Fig. 1B) . This could indicate that in MDA-MB 468 cells, which have high p-4E-BP1 levels, most eIF4E should be free to associate with eIF4G and promote eIF4F complex formation.
To assess the relevance of eIF4E phosphorylation when eIF4E binds to 4E-BP1 or eIF4G, we performed immunoprecipitation of MDA-MB 231 and MDA-MB 468 from cell lysates. The results showed that there were some differences between the cell lines. More p-eIF4E was bound to 4E-BP1 in MDA-MB 231 than in MDA-MB 468 ( Fig. 2A) . However, when eIF4E was analyzed after immunoprecipitation of eIF4G and p-eIF4G, similar results were found in the two cell lines tested. eIF4E and p-eIF4E bound to p-eIF4G at Ser1108 at similar levels in both breast cell lines (Fig. 2B and C) .
Overexpression of wild-type and mutant 4E-BP1 in cell lines
and its association with cell proliferation and p-eIF4E. The phosphorylation status of 4E-BP1 determines the affinity for eIF4E. Presence of phosphates on the Thr 37/46 residues is necessary to phosphorylate the protein's carboxy-terminal sites, Thr 70 and Ser 65. To determine the importance of these phosphorylation sites on cell proliferation, the two breast cancer lines and IMR90 were infected with retroviral vectors carrying a pBABE-4E-BP1wt and pBABE-4E-BP1 (4 Ala). 4E-BP1 (4 Ala) is a mutated variant of the protein in which Thr37/46, Thr70 and Ser65 are replaced by Ala. The resulting mutated 4E-BP1, 4E-BP1mut, binds constitutively to eIF4E and inhibits translation initiation. In IMR90 cells, 4E-BP1 expression led to a decrease in proliferation compared to cells expressing the empty vector. Moreover, the effect on cell proliferation was higher when the constitutive translational repressor 4E-BP1mut was expressed (Fig. 3A) . In breast carcinoma cells, the proliferation decrease after 4E-BP1 overexpression was higher in MDA-MB 468 than in MDA-MB 231 cells, which did not show any significant effect after 4E-BP1 transduction (Fig. 3B and C) . The differences in molecular stoichiometry observed in these cell lines, such as hyperphosphorylation of 4E-BP1 and low p-eIF4E levels in MDA-MB 468 and IMR90 cells, could explain the differences observed after 4E-BP1 transduction. MDA-MB 231 cells, which were resistant to the translational repressor, presented low p-4E-BP1 levels and high p-eIF4E levels. This difference may be explained by variations in the signaling pathways of these cells due to their activation status or molecular stoichiometry. MDA-MB 468 cells harbor mutations in PTEN and high levels of p-4E-BP1, and MDA-MB 231 cells have KRAS mutations and high p-eIF4E.
In addition, the ratio of hypophosphorylated 4E-BP1 to eIF4E was calculated by densitometry. Cells with decreased proliferation, such as MDA-MB 468 cells with 4E-BP1 wt or mut, had a ratio close to 1, indicating a lack of free eIF4E for translation initiation, whereas proliferative cells presented ratios below 0.6, indicating abundant free eIF4E (Fig. 3D) . Hemagglutinin immunoblotting confirmed ectopic HA 4E-BP1 expression, whereas cells infected with null vector showed no HA expression.
Effect of p-eIF4E on cell proliferation. Because MDA-MB 231 and MDA-MB 468 cells presented different baseline p-eIF4E levels, we analyzed the status of eIF4E phosphorylation in cells that overexpressed the pBABE-4E-BP1 wt and mutant 4E-BP1 form [pBABE-4E-BP1 (4 Ala)]. The two cell lines tested showed some differences. MDA-MB 468 cells transduced with pBABE-4E-BP1 (4 Ala) and pBABE-4E-BP1 wt showed downregulation of eIF4E phosphorylation compared to cells transduced with pBABE null, the effect being more evident after pBABE-4E-BP1 (4 Ala) transduction, where p-eIF4E levels were almost undetectable after 7 days. Conversely, MDA-MB 231 cells did not show any differences in p-eIF4E levels after 4E-BP1 transduction (Fig. 4A) .
As is described in Fig. 3B , overexpression of wt and mutant 4E-BP1 in MDA-MB 468 caused a decrease in cell proliferation and correlated with the low levels of p-eIF4E. We then set out to determine whether p-eIF4E level was associated with in vitro cell growth. MDA-MB 468 and MDA-MB 231 cells were treated with the MNK inhibitor CGP57380 to inhibit eIF4E phosphorylation. p-eIF4E was downregulated after 12 h (Fig. 4B) . Interestingly, cells showed decreased growth and formed much more compact, three-dimensional plaques after inhibitor treatment. The differences relative to untreated cells were evident: cells with p-eIF4E showed more irregular cell clusters and spreading out of cells from the clusters. These cytological features are similar to those observed in well differentiated adenocarcinomas, and this suggested that some cell adhesion proteins, such as E-cadherin and/or β-catenin might be upregulated. To check this hypothesis, Western blotting was used to analyze E-cadherin and β-catenin levels in MDA-MB 468 cells and β-catenin in MDA-MB 231 cells (these cells do not express E-cadherin) (Fig. 4B) . The results showed an increase in the two proteins after CGP57380 treatment. Similar results were observed in a colon carcinoma cell line (HT-29) (data not shown). To correlate E-cadherin and β-catenin expression with p-eIF4E levels, we analyzed levels of these factors in MDA-MB 468 cells overexpressing pBABE-4E-BP1 (4 Ala) after 7 days post-transduction, when p-eIF4E was almost undetectable. Interestingly, at this time, MDA-MB 468 cells infected with pBABE-4E-BP1 (4Ala) displayed increased E-cadherin and β-catenin expression, similar to the effect observed after inhibition of p-eIF4E with CGP57380 (Fig. 4C) .
Xenograft tumor growth. To investigate the effects of 4E-BP1
in vivo, MDA-MB 231 and MDA-MB 468 cells transduced with pBABE-4E-BP1 wt or pBABE-4E-BP1 (4 Ala) were injected into the flanks of nude mice, and tumor growth was evaluated. study time course were not statistically significant (Fig. 5A) . MDA-MB 468 cells formed tumors with a latency period of 7 days, whereas cells expressing 4E-BP1wt or 4E-BP1mut formed tumors with much longer latency. MDA-MB 468 tumors formed by 4E-BP1wt cells were first apparent on day 12, whereas tumors formed by 4E-BP1mut did not appear until day 26 after injection. In the MDA-MB 468 cell model, tumors expressing 4E-BP1wt or 4E-BP1mut were significantly smaller than tumors with empty vector at days 7 and 26 after injection (Kruskal-Wallis test, p=0.0042, p=0.0035, respectively) (Fig. 5B) . Moreover, tumor size in mice with 4E-BP1mut was statistically different from that of mice with the empty vector at day 54 (Kruskal-Wallis test, p=0.0128), even though small tumors were already observed. Conversely, the tumor size in mice with 4E-BP1 wt at day 54 was not statistically significantly smaller compared to mice with the empty vector (pBABE). This could suggest that the power of tumor formation is dependent on loss of the hypophosphorylated forms of 4E-BP1; the differences in tumor size in mice with 4E-BP1 mutant, which cannot be phosphorylated, were evident until the end of the experiment.
Discussion
The findings of this study further support the concept that high levels of p-4E-BP1 and eIF4E are associated with cell proliferation (1-4,7,16,23,24) . Moreover, our data provide new insight into the role of p-eIF4E in human carcinoma cell lines and the association of this factor with tumor aggressiveness and resistance to the tumor-suppressor effect of 4E-BP1.
We performed in vivo and in vitro experimental analyses with a wt and a mutated form of 4E-BP1 at phosphorylation sites that bind to eIF4E, blocking eIF4E activity. In normal cells (IMR90 fibroblasts) ectopic expression of 4E-BP1wt suppressed cell proliferation. In addition, pBABE-4E-BP1 (4Ala) transduction induced a decrease in cell proliferation relative to that of cells with 4E-BP1wt. It is important to note that binding of eIF4E with mutant 4E-BP1, which cannot be phosphorylated at sites Thr37, Thr46, Thr70, or Ser65, induced a clear loss of viability in normal cells, where cap-dependent translation seems to be crucial (9) . In malignant cells, cell death did not occur after transduction of 4E-BP1mut, but cell proliferation decreased and tumorigenicity was delayed. This effect was stronger in MDA-MB 468 breast cancer cells than in MDA-MB 231, where no significant effect was observed. Interestingly, the in vitro and in vivo experiments showed similar results. A previous study by Avdulov et al (9) also reported in vitro antiproliferative activity of 4E-BP1 in the same breast carcinoma cells used in the present study. Furthermore, these authors observed that transfer of 4E-BP1 phosphorylation site mutants into MDA-MB 468 cells suppressed their tumorigenicity. However, the mutant used in that study was A37/A46, whereas in the present study a mutant in all the 4E-BP1 phosphorylation sites was used, since the two ultimate phosphorylations, at Thr70 and Ser65, are considered responsible for eIF4E dissociation.
Our in vivo experiments were stopped at 54 days post-injection. We found that tumorigenicity suppression is maintained up to 54 days in MDA-MB 468 cells with 4E-BP1mut. In MDA-MB 231 cells, suppression of tumorigenicity was not so evident and disappeared by day 54. Interestingly, MDA-MB 468 cells harbor mutations at the PTEN gene, which most probably is constitutively activating mTOR and therefore, phosphorylation of 4E-BP1, as was observed. We suggest that these cells are more sensitive to 4E-BP1 phosphorylation than MDA-MB 231 cells, which had lower baseline levels of Ser65 4E-BP1. It is likely that hypophosphorylated 4E-BP1 bound to eIF4E; hence, overexpression of 4E-BP1 (normal or mutated) had no effect on cell growth. We observed that cells with decreased proliferation, such as MDA-MB 468 cells with 4E-BP1 wt or mut, had a ratio close to 1, which indicates a lack of free eIF4E for translation initiation. On the other hand, proliferative cells presented ratios below 0.6, indicating abundant free eIF4E.
Moreover, MDA-MB 231 cells could be using cell signaling pathways other than 4E-BP1 phosphorylation. Of note, these cells have mutations at the KRAS gene and therefore, could be more MAPK-dependent.
Because we also observed some differences in baseline p-eIF4E in the two breast carcinoma lines studied, we extended our studies in an attempt to understand the contribution of p-eIF4E in enhancing cell proliferation. The biochemical pathways underlying the role of p-eIF4E in malignant tumors remain unclear and the biological significance of eIF4E phosphorylation and its effect on translation is controversial (15, 18, 25) . eIF4E phosphorylation is dispensable for mouse development (26) , but seems to be important for normal development in Drosophila (27) . In a cell culture study by Borden et al, nuclear eIF4E phosphorylation was seen to enhance the mRNA transport function and transformation activity of eIF4E (28) , and eIF4E is reported to promote export of ODC and cyclin D1 from the nucleus to the cytoplasm (29) . Thus, phosphorylation of nuclear eIF4E seems to be an important step in mRNA transport control, and consequently, in the transforming properties of eIF4E. Tumorigenesis in transgenic eIF4E-expressing mice is markedly increased, leading to the development of lymphomas (30) . This transforming activity of eIF4E has been associated with its phosphorylation (18, 31) and with c-myc co-activation (30) . In fact, eIF4E phosphorylation has been linked to suppression of apoptosis by an increase in the antiapoptotic protein MCL1 (18) .
Another biochemical mechanism that could explain the role of p-eIF4E in transformation is the fact that p-eIF4E does not bind as strongly to 4E-BP1 as total eIF4E does, at least in some cell types. Previously it was reported that p-eIF4E binds more efficiently to capped mRNAs (17) , suggesting that the affinity of phosphorylated eIF4E for 4E-BP1 is decreased. Moreover, Chen et al (19) reported that p-eIF4E binds less well to 4E-BP1 than the unphosphorylated form. In our coimmunoprecipitation and Western blot studies, p-eIF4E seemed to show a weaker affinity for 4E-BP1 than total eIF4E in MDA-MB 468 cells, but not in MDA-MB 231 cells. MDA-MB 468 were much more sensitive to the suppressor effect of 4E-BP1mut, and this sensitivity correlated with baseline p-eIF4E levels. MDA-MB 231 cells presented higher p-eIF4E levels than MDA-MB 468 cells. Moreover, when 4E-BP1wt and mutant were overexpressed in MDA-MB 468 cells, p-eIF4E levels clearly decreased. In a more extensive study, we also observed that high levels of peIF4E associate with resistance to overexpression of 4E-BP1 in some carcinoma cell lines (data not shown) and support the idea that lower affinity of p-eIF4E to 4E-BP1 could be related to a biochemical pathway to override the suppressor effect of 4E-BP1. eIF4E is phosphorylated by the MNKs, which are activated through the classic MAP kinase pathway (ERK1, 2) and the stress-activated MAP kinase pathway (p38 MAP kinase) (15, 26, 32) . In addition to eIF4E, other MNK substrates (e.g. hnRNPA1) are involved in translational control (33) , and MNKs seem to play a crucial role in regulation of specific mRNAs, rather than in general translation (34) . Because treatment with MNK inhibitor induced a decrease in cell growth in our model and cells acquired more compact clusters, we hypothesized that treated cells might overexpress cell adhesion proteins, such as E-cadherin and β-catenin (35) . Effectively, we found that the entire cell membrane of MDA-MB 468 strongly expressed E-cadherin and β-catenin after treatment with the inhibitor. A similar pattern was observed in MDA-MB 468 cells transduced with pBABE-4E-BP1 (4Ala), 7 days after transduction, which exhibited lower levels of p-eIF4E. Interestingly, in MDA-MB 231 cells, which lack expression of E-cadherin, an increase of β-catenin was detected after CGP57380 treatment. These findings could explain the more aggressive behavior of tumors harboring high levels of p-eIF4E and its association with a more mesenchymal phenotype. However, further studies are needed to describe the biochemical pathways and factors involved in upregulation of E-cadherin and β-catenin expression levels observed after treatment with an MNK inhibitor.
In summary, our results show that IMR90 and MDA-MB 468 breast cancer cell lines were sensitive to 4E-BP1 transduction and it correlates with low p-eIF4E levels. We propose that high levels of p-4E-BP1, which does not bind to eIF4E, and high levels of p-eIF4E, which can likely bypass the suppressor effect of 4E-BP1, are central factors in cell signaling and reflect the oncogenic potential of these pathways in breast cancer. These results provide evidence that 4E-BP1 and eIF4E phosphorylation inhibitors could be a new group of molecular funnel targets for breast cancer treatment.
